|
|
 Previous Article | Table of Contents | Next Article 
High-dose cyclophosphamide, carmustine, and etoposide followed by
autologous peripheral stem cell transplantation for patients with relapsed
Hodgkin's disease [published erratum appears in Blood 1991 Dec
15;78(12):3330]
A Kessinger, PJ Bierman, JM Vose and JO Armitage
University of Nebraska Medical Center, Omaha 68198-3330.
Between February 1986 and March 1990, 56 patients with relapsed Hodgkin's
disease treated with high-dose cyclophosphamide, carmustine, and etoposide
(CBV) received an autologous peripheral stem cell transplantation (PSCT)
rather than an autologous bone marrow transplantation (ABMT) because each
patient had a marrow abnormality, either hypocellularity or tumor
involvement. At least 6.5 x 10(8) [corrected] mononuclear cells/kg patient
weight were collected from the peripheral blood of each patient,
cyropreserved, and returned intravenously following CBV administration.
Three patients had an early death 2, 22, and 25 days after PSCT. The
actuarial event-free survival for these 56 patients at 3 years was 37% and
was at least as good as that reported for relapsed Hodgkin's disease
patients treated with CBV and ABMT. The 30 patients who had no marrow
metastases at the time of PSC harvesting had an actuarial event-free
survival of 47%, while those 26 patients with marrow metastases had a
significantly different actuarial event-free survival of 27% (P = .02). CBV
and PSCT for patients with relapsed Hodgkin's diseases who have marrow
hypocellularity in traditional harvest sites or histopathologic evidence of
BM metastases can result in long-term event-free survival.
Volume 77,
Issue 11,
pp. 2322-2325,
06/01/1991
Copyright © 1991 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
Y. E. Lieskovsky, S. S. Donaldson, M. A. Torres, R. M. Wong, M. D. Amylon, M. P. Link, and R. Agarwal
High-Dose Therapy and Autologous Hematopoietic Stem-Cell Transplantation for Recurrent or Refractory Pediatric Hodgkin's Disease: Results and Prognostic Indices
J. Clin. Oncol.,
November 15, 2004;
22(22):
4532 - 4540.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Diehl, H. Stein, M. Hummel, R. Zollinger, and J. M. Connors
Hodgkin's Lymphoma: Biology and Treatment Strategies for Primary, Refractory, and Relapsed Disease
Hematology,
January 1, 2003;
2003(1):
225 - 247.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Arpaci, S. Komurcu, B. Ozturk, A. Ozet, C. Kinalp, A. Sengul, M. Beyzadeoglu, Y. Pak, and A. Yalcin
A Successful and Simplified Filgrastim Primed Single Apheresis Method Without Large Volume Apheresis for Peripheral Blood Stem Cell Collection
Jpn. J. Clin. Oncol.,
March 1, 2000;
30(3):
153 - 158.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Rodriguez, M.A. Rodriguez, L. Fayad, P. McLaughlin, F. Swan, A. Sarris, J. Romaguera, B. Andersson, F. Cabanillas, and F.B. Hagemeister
ASHAP: A Regimen for Cytoreduction of Refractory or Recurrent Hodgkin's Disease
Blood,
June 1, 1999;
93(11):
3632 - 3636.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. S. Baker, B. G. Gordon, T. G. Gross, M. A. Abromowitch, E. R. Lyden, J. C. Lynch, J. M. Vose, J. O. Armitage, P. F. Coccia, and P. J. Bierman
Autologous Hematopoietic Stem-Cell Transplantation for Relapsed or Refractory Hodgkin's Disease in Children and Adolescents
J. Clin. Oncol.,
March 1, 1999;
17(3):
825 - 825.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G Mittal, C Balakrishna, G Mangat, and V R Joshi
'Sustained remission' in a case of SLE following megadose cyclophosphamide
Lupus,
January 1, 1999;
8(1):
77 - 80.
[Abstract]
[PDF]
|
|
|
|
|
|
|
H. Tesch, V. Diehl, B. Lathan, D. Hasenclever, M. Sieber, U. Ruffer, A. Engert, J. Franklin, M. Pfreundschuh, K.P. Schalk, et al.
Moderate Dose Escalation for Advanced Stage Hodgkin's Disease Using the Bleomycin, Etoposide, Adriamycin, Cyclophosphamide, Vincristine, Procarbazine, and Prednisone Scheme and Adjuvant Radiotherapy: A Study of the German Hodgkin's Lymphoma Study Group
Blood,
December 15, 1998;
92(12):
4560 - 4567.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
